Advance Search
ZHANG Meiling, PAN Jiadong, ZHANG Dongwei. A randomized controlled clinical study of avatrombopag combined with Shengxue Decoction and selenium yeast in prevention of thrombocytopenia induced by chemotherapy for tumor[J]. Journal of Clinical Medicine in Practice, 2023, 27(4): 104-107, 112. DOI: 10.7619/jcmp.20222826
Citation: ZHANG Meiling, PAN Jiadong, ZHANG Dongwei. A randomized controlled clinical study of avatrombopag combined with Shengxue Decoction and selenium yeast in prevention of thrombocytopenia induced by chemotherapy for tumor[J]. Journal of Clinical Medicine in Practice, 2023, 27(4): 104-107, 112. DOI: 10.7619/jcmp.20222826
shu

A randomized controlled clinical study of avatrombopag combined with Shengxue Decoction and selenium yeast in prevention of thrombocytopenia induced by chemotherapy for tumor

  • 1.

    Department of Oncology, Huoshan County Hospital in Anhui Province, Lu'an, Anhui, 237200

  • 2.

    the First Department of Oncology, the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui, 230031

More Information
  • Received Date: September 07, 2022
  • Available Online: March 14, 2023
    Graphical Abstract
    • Abstract
  • Objective 

    To observe the effect of avatrombopag combined with Shengxue Decoction and selenium yeast in preventing thrombocytopenia induced by chemotherapy for tumor.

    Methods 

    According to different therapeutic methods, 80 patients with chemotherapy for tumor in Huoshan County Hospital from March 2019 to March 2022 were divided into control group and observation group, with 40 cases in each group. The control group was treated with avatrombopag and selenium yeast after chemotherapy, while the observation group was treated with avatrombopag, selenium yeast and Shengxue Decoction after chemotherapy. Effect related indicators were compared between two groups.

    Results 

    In the observation group, the platelet count level and the lowest value of platelet were significantly higher than those in the control group, the time of platelet≤50×109/L and time of platelet≥100×109/L were significantly shorter than those in the control group, while the platelet transfusion rate and the incidence of thrombocytopenia above grade Ⅲ were significantly lower than those in control group (P < 0.05). After treatment, the scores of TCM syndrome such as fatigue and lack of strength, poor appetite and less food intake, and lack of qi and no desire to speak in both groups were significantly lower than those before treatment, and the scores of symptoms mentioned above in the observation group were significantly lower than those in the control group (P < 0.05). The incidence of chemotherapy-related adverse reactions in the observation group was 7.50%, which was significantly lower than 25.00% in the control group (P < 0.05). After treatment, the activated partial thromboplastin time (APTT) and prothrombin time (PT) in both groups were significantly shorter than those before treatment, while the fibrinogen (FIB) was significantly higher than that before treatment, and the APTT in the observation group was significantly shorter than that in the control group, while the FIB was significantly higher than that in the control group (P < 0.05).

    Conclusion 

    For the prevention and treatment of patients with thrombocytopenia induced by chemotherapy for tumor, application of avatrombopag combined with Shengxue Decoction and selenium yeast can help promote elevation of platelet, shorten recovery time of platelet, reduce the incidence of thrombocytopenia, and decrease chemotherapy-related adverse reactions.

    • FullText(HTML)
    • References (20)
  • [1]
    张莉, 张玉晶, 王继金, 等. 胃癌同期放化疗所致血小板减少危险因素分析[J]. 中华放射肿瘤学杂志, 2022, 31(2): 160-164.
    [2]
    韩瑛, 张晶, 李淑敏, 等. 重组人血小板生成素预防卵巢癌化疗相关血小板减少症的疗效和安全性[J]. 现代肿瘤医学, 2022, 30(10): 1855-1859. https://www.cnki.com.cn/Article/CJFDTOTAL-SXZL202210028.htm
    [3]
    刘丹娜, 陈露, 苏田丽, 等. 肺癌化疗所致血小板减少症二级预防方案中重组人血小板生成素使用频次的优化[J]. 药学服务与研究, 2022, 22(1): 29-33. https://www.cnki.com.cn/Article/CJFDTOTAL-YXFY202201006.htm
    [4]
    AL-SAMKARI H, SOFF G A. Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia[J]. Expert Rev Hematol, 2021, 14(5): 437-448. doi: 10.1080/17474086.2021.1924053
    [5]
    李红梅, 余文熙, 彭志刚, 等. 阿伐曲泊帕治疗肿瘤化疗所致血小板减少症的疗效及安全性的回顾性研究[J]. 肿瘤, 2021, 41(12): 832-839. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZLL202112005.htm
    [6]
    JIANG Y J, SONG J Q, WANG N, et al. Rituximab-induced acute thrombocytopenia in patients with splenomegaly B Cell lymphoma: an underdiagnosed but severe complication[J]. Cancer Biol Ther, 2020, 21(11): 1060-1066. doi: 10.1080/15384047.2020.1832017
    [7]
    史艳侠, 邢镨元, 张俊, 等. 中国肿瘤化疗相关性血小板减少症专家诊疗共识(2019版)[J]. 中国肿瘤临床, 2019, 46(18): 923-929. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZL201918002.htm
    [8]
    郑筱萸. 中药新药临床研究指导原则(试行)[S]. 上海: 上海科学技术出版社, 2002: 180-184.
    [9]
    黄月华, 张苗苗, 李利红, 等. 艾曲泊帕在实体肿瘤化疗所致血小板减少症治疗中的应用[J]. 肿瘤研究与临床, 2020, 32(9): 652-654.
    [10]
    巩润泽, 刘媛, 张鹏, 等. 重组人血小板生成素二级预防阿帕替尼联合化疗治疗晚期骨与软组织肉瘤患者血小板减少症的疗效分析[J]. 临床肿瘤学杂志, 2022, 27(1): 45-48. https://www.cnki.com.cn/Article/CJFDTOTAL-LCZL202201007.htm
    [11]
    SONG J C, LIU S Y, ZHU F, et al. Expert consensus on the diagnosis and treatment of thrombocytopenia in adult critical care patients in China[J]. 军事医学研究: 英文版, 2020(3): 283-302. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGAZ202201012.htm
    [12]
    杨宏, 孔天东, 陈露, 等. 重组人血小板生成素对化疗所致血小板减少症的预防方案优化研究[J]. 药物评价研究, 2022, 45(1): 98-103. https://www.cnki.com.cn/Article/CJFDTOTAL-YWPJ202201012.htm
    [13]
    王少怡, 余自强. 血小板生成素受体激动剂的研究现状及临床应用[J]. 国际输血及血液学杂志, 2020, 43(2): 122-128. https://www.cnki.com.cn/Article/CJFDTOTAL-EKYX201504022.htm
    [14]
    王永帅, 张赛, 李磊, 等. 阿伐曲泊帕联合重组人血小板生成素和阿伐曲泊帕单药治疗慢性肝病相关重度血小板减少症的临床疗效[J]. 中华消化外科杂志, 2022, 21(2): 281-286.
    [15]
    ZHANG M, ZHANG Y, ZHENG E, et al. Outcomes and costs following ommaya placement with thrombocytopenia among U. S. patients with cancer[J]. World Neurosurg, 2020, 135: e548-e561.
    [16]
    陈灿, 张其坤, 许青. 新型血小板生成素受体激动剂: 阿伐曲泊帕[J]. 中国新药与临床杂志, 2020, 39(11): 652-656. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202011004.htm
    [17]
    王圆, 杜淑旭, 孙艳玲, 等. 重组人血小板生成素皮下注射对脑肿瘤化疗患儿血小板减少症的预防效果[J]. 山东医药, 2021, 61(36): 48-50. https://www.cnki.com.cn/Article/CJFDTOTAL-SDYY202136012.htm
    [18]
    客蕊, 张旭明, 迟庆滨. 中医药防治恶性肿瘤化疗后血小板减少症的研究进展[J]. 江苏中医药, 2021, 53(9): 77-81. https://www.cnki.com.cn/Article/CJFDTOTAL-JSZY202109026.htm
    [19]
    张晶, 罗昌国, 王济国, 等. 升板汤治疗化疗所致血小板减少症的临床研究[J]. 辽宁中医杂志, 2021, 48(12): 133-136. https://www.cnki.com.cn/Article/CJFDTOTAL-LNZY202112038.htm
    [20]
    徐昌静, 刘鑫, 钟小燕, 等. 阿伐曲泊帕治疗慢性肝病血小板减少症的疗效与安全性的系统评价[J]. 中国新药与临床杂志, 2020, 39(11): 688-692. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202011013.htm
    • Related Articles

  • Related Articles

    [1]GUO Ji, LYU Yong. Clinical value of novel bunyavirus load combined with platelet count and thrombin time on prognosis of fever patients complicating with thrombocytopenia syndrome[J]. Journal of Clinical Medicine in Practice, 2024, 28(15): 9-13. DOI: 10.7619/jcmp.20240907
    [2]ZHANG Haiqin, WANG Haibo, GU Yongmei. Construction and validation of a Nomogram for prognosis of patients with severe thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2023, 27(3): 75-80. DOI: 10.7619/jcmp.20222359
    [3]XU Jianhong, CHEN Yuanfeng, ZHU Qing, LIU Lili, LIU Hong, QIAO Mingming. Value of long non-coding RNA TMEVPG1 in prognosis evaluation of patients with primary immune thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2023, 27(3): 16-20. DOI: 10.7619/jcmp.20221880
    [4]ZHOU Mo, SHAO Yu, SHAN Xueyun, WANG Pin, SUN Naitong. Effect of eltrombopag combined with cyclosporin in treatment of patients with refractory immune thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 51-53. DOI: 10.7619/jcmp.20214694
    [5]HE Suli, LI Yuanyuan, HE Jiameng, SUN Ru, LIU Haiyan. A case of acute thrombocytopenia caused by iodine contrast agent[J]. Journal of Clinical Medicine in Practice, 2022, 26(4): 133-135. DOI: 10.7619/jcmp.20212547
    [6]HAO Caixia. Comparision of four types of immunosuppressive agents in treating patients with primary immune thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2020, 24(24): 100-102. DOI: 10.7619/jcmp.202024030
    [7]YU Xiuxia, CAO Xiaoming. Correlation between Helicobacter pylori infection and immune thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2020, 24(2): 108-110. DOI: 10.7619/jcmp.202002031
    [8]MENG Huan. Comprehensive nursing intervention in patients with refractory immune thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2018, (18): 39-42. DOI: 10.7619/jcmp.201818012
    [9]ZHANG Qing, GAO Changjun. Expression of T lymphocyte subsets, NK cells and B cells in peripheral blood of children with primary immunologic thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2017, (17): 45-47. DOI: 10.7619/jcmp.201717013
    [10]JI Meihua, TAO Jian, CHEN Jin, HUANG Quan, MA Haijia. Significance of platelet parameters in the diagnosis and efficacy-evaluation of adult patients with severe primary mmune thrombocytopenia[J]. Journal of Clinical Medicine in Practice, 2014, (15): 140-142. DOI: 10.7619/jcmp.201415048

  • Cited by

    Periodical cited type(5)

    1. 王亚敏. 海曲泊帕乙醇胺片联合rhTPO治疗实体瘤化疗后血小板减少症患者的临床研究. 中国医学创新. 2024(14): 65-68 .
    2. 刘媛媛，刘营. 马来酸阿伐曲泊帕联合磷酸芦可替尼对骨髓纤维化的治疗效果及对免疫功能和血清炎性因子影响. 医学理论与实践. 2024(14): 2393-2396 .
    3. 段秀芳，唐胜军，苑馨. 海曲泊帕治疗实体瘤化疗所致血小板减少症的效果分析. 系统医学. 2024(15): 166-168+176 .
    4. 侯燕敏，郭连萍. 黄芪对结直肠癌化疗患者免疫功能及不良反应的影响. 实用中医内科杂志. 2023(12): 118-120 .
    5. 陈丽如，丁丽丽，叶文峰，朱明炜. 微营养素在恶性肿瘤营养治疗中的应用现状. 中华临床营养杂志. 2023(06): 378-382 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (213) PDF downloads (14) Cited by(5)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return